Literature DB >> 23552479

A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.

Lindsay LaPresto1, Lee Cranmer, Lynne Morrison, Christof P Erickson, Clara Curiel-Lewandrowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23552479      PMCID： PMC4575122          DOI： 10.1001/jamadermatol.2013.2583

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

Review 1.  Intralesional agents in the management of cutaneous malignancy: a review.

Authors:  Laurie M Good; Misha D Miller; Whitney A High
Journal:  J Am Acad Dermatol       Date:  2010-03-23       Impact factor: 11.527

2.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

3.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

4.  Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study.

Authors:  J N Bavinck; L M Tieben; F J Van der Woude; A M Tegzess; J Hermans; J ter Schegget; B J Vermeer
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

5.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245
  5 in total
  3 in total

Review 1.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

2.  Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin.

Authors:  Hélène Mascitti; Adèle De Masson; Florence Brunet-Possenti; Jean-David Bouaziz; Pauline Laly; Nadim Mourad; Jean-Michel Garrigues; Sara Laurent-Roussel; Bénédicte Cavelier-Balloy; Isabelle Moulonguet; Cristina Leschi; Samia Mourah; Martine Bagot; Céleste Lebbé; Nicole Basset-Seguin
Journal:  Dermatol Ther (Heidelb)       Date:  2019-02-21

3.  Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence.

Authors:  Caroline Siviero Dillenburg; Manoela Domingues Martins; Luise Meurer; Rogerio Moraes Castilho; Cristiane Helena Squarize
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.